MEDLINE/PubMed Journal Browser Search

Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

Title: Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes.
Author: Xie Z, Qin Y, Chen X, Yang S, Yang J, Gui L, Liu P, He X, Zhou S, Zhang C, Tang L, Shi Y.
Journal: Target Oncol; 2024 May; 19(3):383-400. PubMed ID: 38643457.
Abstract:
BACKGROUND: The clinical and genetic characteristics, as well as treatment outcomes, of diffuse large B-cell lymphoma (DLBCL) patients with different MYD88 and CD79B mutation status merit further investigation. OBJECTIVE: This study aims to investigate the distinctions in clinical manifestations, genetic characteristics, and treatment outcomes among MYD88-CD79B^co-mut, MYD88/CD79B^single-mut, and MYD88-CD79B^co-wt DLBCL patients. PATIENTS AND METHODS: Clinical and genetic characteristics, along with treatment outcomes among 2696 DLBCL patients bearing MYD88-CD79B^co-mut, MYD88/CD79B^single-mut, and MYD88-CD79B^co-wt treated with R-CHOP/R-CHOP-like regimens from the Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College and six external cohorts were analyzed. Potential molecular mechanisms were investigated through Gene Set Enrichment Analysis and xCell methodology. RESULTS: In the MCD subtype, patients with MYD88-CD79B^co-mut showed comparable progression-free survival (PFS) and overall survival (OS) compared to MYD88/CD79B^single-mut or MYD88-CD79B^co-wt. However, in the non-MCD subtype, patients with MYD88-CD79B^co-mut exhibited significantly inferior OS than MYD88/CD79B^single-mut or MYD88-CD79B^co-wt, while there was no significant OS difference between MYD88/CD79B^single-mut and MYD88-CD79B^co-wt (median OS: 68.8 [95% CI 22-NA] vs NA [95% CI 112-NA] vs 177.7 [95% CI 159-NA] months; MYD88-CD79B^co-mut vs MYD88/CD79B^single-mut: p = 0.02; MYD88-CD79B^co-mut vs MYD88-CD79B^co-wt: p = 0.03; MYD88/CD79B^single-mut vs MYD88-CD79B^co-wt: p = 0.33). Regarding patients with MYD88-CD79B^co-mut, there was no significant difference in PFS and OS between the MCD and non-MCD subtypes. Within the MYD88-CD79B^co-mut group, patients with PIM1^mut had better PFS than PIM1^wt (median PFS: 8.34 [95% CI 5.56-NA] vs 43.8 [95% CI 26.4-NA] months; p = 0.02). Possible mechanisms contributing to the superior PFS of PIM1^mut patients may include activated lymphocyte-mediated immunity and interferon response, a higher proportion of natural killer T cells and plasmacytoid dendritic cells, as well as suppressed angiogenesis and epithelial-mesenchymal transition, along with lower fibroblast and stromal score. CONCLUSIONS: In the MCD subtype, patients with MYD88-CD79B^co-mut showed comparable PFS and OS compared to MYD88/CD79B^single-mut or MYD88-CD79B^co-wt, while in the non-MCD subtype, they exhibited significantly inferior OS. There was no significant disparity in PFS and OS of MYD88-CD79B^co-mut between the MCD and non-MCD subtypes. The presence of PIM1^mut within the MYD88-CD79B^co-mut group correlated with better PFS, which may result from an intricate interplay of immune processes and tumor microenvironment alterations.

[Abstract] [Full Text] [Related] [New Search]